Pfiz­er blue­prints $200M R&D cam­pus; Gala­pa­gos bags $50M mile­stone from Gilead

Pfiz­er is build­ing a new R&D cam­pus in St. Louis for more than 600 staffers cur­rent­ly de­ployed at two near­by lo­ca­tions. This new con­sol­i­da­tion project will cost more than $200 mil­lion.

The Bel­gian biotech Gala­pa­gos and its part­ners at Gilead have dosed their first pa­tient in a Phase III study of their close­ly-watched drug fil­go­tinib for Crohn’s dis­ease. Gilead, which has ex­pe­ri­enced a slate of clin­i­cal set­backs this year, is hand­ing over a $50 mil­lion mile­stone to mark the start of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER